Protocol Ledger

NCT05691712 · Phase III · COMPLETED

A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes

Interventional Phase III clinical trial protocol NCT05691712 sponsored by Eli Lilly and Company in Endocrinology, Obesity, and Metabolic, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-02-05 Enrollment: 257 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05691712
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)257 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05691712
Protocol FieldVerified Registry Value
NCT IdentifierNCT05691712
Consolidated Lead SponsorEli Lilly and Company
Therapeutic Condition CohortEndocrinology, Obesity, and Metabolic
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment257 participants (ACTUAL)
Registered Start Date2023-02-05
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05691712
Hospital Research SiteLocationSite Profile
Beijing HospitalBeijing, ChinaOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Eli Lilly and Company across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Endocrinology, Obesity, and Metabolic Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI